The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Remote Use of the Multidimensional Health Assessment Questionnaire (MDHAQ)

Remote Use of the Multidimensional Health Assessment Questionnaire (MDHAQ)

December 18, 2019 • By Juan Schmukler, MD, & Theodore Pincus, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Case Report

Pixsooz / shutterstock.com

Pixsooz / shutterstock.com

A 78-year-old man with pulmonary fibrosis was referred to a rheumatologist on Jan. 19, 2018, because of a positive rheumatoid factor test. His joint examination was normal. Although reassured he did not have RA, he asked to be monitored by both a rheumatologist and a pulmonologist.

You Might Also Like
  • How Does Health Literacy Affect the Patient Global Assessment?
  • The Science of MDHAQ/RAPID3 Scores
  • Telemedicine Company Wins Order Putting Texas Remote Treatment Rule on Hold
Explore This Issue
December 2019

All patients with all diagnoses seen in the rheumatology division at Rush University Medical Center complete an MDHAQ at all routine visits. At the patient’s first visit, his RAPID3 score was 14/30 (high severity = 12–30), his fatigue score on the 0–10 VNS was 7/10, and he reported 10/60 symptoms (see Figure 2, below).6 He was treated with low-dose prednisone and methotrexate, experiencing substantial clinical improvement over the next six months, which was documented on the MDHAQ. On Aug. 2, the RAPID3 score was 3.5/30 (low severity = 3.1–6.0), his fatigue score was 2/10, and he reported 6/60 symptoms (see Figure 2, below), although he continued to require low-level oxygen.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

On Aug. 15, his pulmonologist discontinued low-dose prednisone and methotrexate and prescribed 267 mg pills of pirfenidone (Esbriet), an anti-fibrotic agent, escalated over three weeks: three pills the first week, six the second and nine the third (see Figure 2, below).16 His next rheumatology appointment was scheduled for October.

On Sept. 24, the patient telephoned the rheumatologist to report many new problems, although his pulmonary status was mostly unchanged—continuing to require oxygen. The rheumatologist sent the patient an electronic MDHAQ for completion at home to characterize his clinical status quantitatively for comparison with the Aug. 2 report. His new RAPID3 score was 19.5/30 vs. 3.5/30 on Aug. 2, his fatigue score was 9/10 vs. 2/10, and he reported 15/60 vs. 6/60 symptoms (see Figure 2). Seven of the nine new symptoms (not reported on Aug. 2) were among 16 adverse events listed for pirfenidone on the manufacturer’s website (see Figure 3). These included weight loss, anorexia, unusual fatigue, abdominal pain, indigestion, heartburn and insomnia (see Figure 2).

Figure 2: Patient’s MDHAQ Results over 2018

(click for larger image) Figure 2: Patient’s MDHAQ Results over 2018

The rheumatologist advised discontinuation of pirfenidone, reinstatement of 10 mg/day of prednisone and remote electronic MDHAQ monitoring two and five days later, with a plan for a face-to-face visit if no improvement was apparent. Five days later, his RAPID3 had improved from 19.5/30 to 8/30 and his fatigue score improved from 9/10 to 4/10 (see Figure 2).

Weekly remote electronic MDHAQ monitoring was instituted, which docu­mented clinical improvement according to RAPID3 and resolution of most pirfenidone-related symptoms over the next 10 weeks (see Figure 2).

A brief retrial of pirfenidone was followed by an increase of the RAPID3 score to 6.0 and was discontinued in a timely manner (see Figure 2, opposite). On Dec. 28 (after methotrexate was reinstated), the patient’s RAPID3 was 4.2/30, his fatigue score was 2.0/10, and he reported 6/60 symptoms.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 4 5 | Single Page

Filed Under: Conditions, Technology Tagged With: case report, Multidimensional Health Assessment Questionnaire (MDHAQ), Routine Assessment of Patient Index Data (RAPID)Issue: December 2019

You Might Also Like:
  • How Does Health Literacy Affect the Patient Global Assessment?
  • The Science of MDHAQ/RAPID3 Scores
  • Telemedicine Company Wins Order Putting Texas Remote Treatment Rule on Hold
  • ACR Publishes Disease Activity and Functional Status Assessment Measure Recommendations for RA

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)